NY
Nymox Pharmaceutical Corporation
NYMXF · OTC
$0.10 +0.00% (+$0.00)
1M +49,900.00%
Market Cap $1.89M
P/E Ratio -
Div. Yield -
ROE -
Bulios Fair Price
$0.05
50.0% downside
Current Price
$0.1
Undervalued Fair Value Overvalued
According to Bulios Fair Price, NYMXF is currently overvalued relative to its market price. How does it work?
Bulios Fair Price is an estimate of a stock's fair value from the Bulios valuation model. It is an input for your own analysis, not investment advice. How does it work?
Analysis
An AI report on the business, its finances, valuation, sentiment, news and risks - written in a few minutes.
Piotroski F-Score Weak
2/9Valuation
-
N/A P/B N/A
EV/FFO N/A
P/E N/A
Growth
-
N/A Book val. growth N/A
FCF growth N/A
EPS growth N/A
Profitability
-
N/A FCF margin N/A
Op. margin N/A
Gross margin N/A
Quality
57 /100
Average ROA 686.85%
Asset turnover 0.00x
ROIC 63.22%
Debt
0 /100
High Int. coverage -18.88x
Current ratio 0.09x
Net debt/EBITDA N/A
Stability
18 /100
Unstable EPS volatility 47.18%
Profitable years 0
Beta 8.90x
Bulios Scoring describes a company's quality and track record, not its future return. A high score is not a buy signal. Learn more
Ask StockBot about NYMXF
Online
Sector
Healthcare
Industry
Biotechnology
CEO
Paul Averback
Employees
16
Headquarters
Nassau